胰腺癌中与巨噬细胞和脂质代谢相关的预后和治疗生物标志物的鉴定
Identification of prognostic and therapeutic biomarkers associated with macrophage and lipid metabolism in pancreatic cancer.
作者信息
Wu Lili, Liang Feihong, Chen Changgan, Zhang Yaxin, Huang Heguang, Pan Yu
机构信息
Department of Surgical Nursing, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Department of General Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, People's Republic of China.
出版信息
Sci Rep. 2025 Apr 25;15(1):14584. doi: 10.1038/s41598-025-99144-z.
Although macrophages and lipid metabolism significantly influence the progression of various cancers, their precise roles in pancreatic cancer (PC) remain unclear. This study focuses on identifying and validating biomarkers associated with macrophage-related genes (MRGs) and lipid metabolism-related genes (LMRGs), providing new targets and strategies for therapeutic intervention. This research utilized datasets from TCGA-PAAD, GSE62452, and GSE57495. Candidate genes were identified by overlapping differentially expressed genes with MRGs from WGCNA and LMRGs. Regression analyses were performed to pinpoint potential biomarkers and construct a risk model, which underwent evaluation. A nomogram was subsequently developed and validated. Additional analyses, including functional enrichment, somatic mutation profiling, immune landscape assessment, and RT-qPCR, were performed to investigate the underlying biological mechanisms in PC. The study identified ADH1A, ACACB, CD36, CERS4, PDE3B, ALOX5, and CRAT as biomarkers for PC. RT-qPCR results revealed reduced expression of ADH1A, ACACB, CD36, CERS4, PDE3B, and CRAT in tumor samples compared to adjacent tissues, whereas ALOX5 expression was significantly elevated in tumor samples. A risk model utilizing these biomarkers classified PC patients into high- and low-risk cohorts, with high-risk patients showing lower survival probabilities. Subsequently, risk score and N stage were identified as independent prognostic factors, leading to the development of a nomogram. Notably, both risk cohorts showed significant enrichment in the "cell cycle" pathway. Furthermore, TP53 mutations were prevalent in both high-risk (76%) and low-risk (50%) cohorts. Correlation analysis indicated that PVRL2 (an immunosuppressive factor), CD276 (an immunoactivator), and CCL20 (a chemotactic factor) had the highest positive correlation with the risk score. In this study, ADH1A, ACACB, CD36, CERS4, PDE3B, ALOX5, and CRAT were identified as biomarkers for PC, with their expression levels validated in clinical samples. These findings offered a potential theoretical foundation for developing targeted treatments for PC.
尽管巨噬细胞和脂质代谢对多种癌症的进展有显著影响,但其在胰腺癌(PC)中的具体作用仍不清楚。本研究着重于识别和验证与巨噬细胞相关基因(MRGs)和脂质代谢相关基因(LMRGs)相关的生物标志物,为治疗干预提供新的靶点和策略。本研究使用了来自TCGA-PAAD、GSE62452和GSE57495的数据集。通过将差异表达基因与来自WGCNA的MRGs和LMRGs进行重叠来鉴定候选基因。进行回归分析以确定潜在的生物标志物并构建风险模型,并对其进行评估。随后开发并验证了列线图。还进行了其他分析,包括功能富集、体细胞突变分析、免疫景观评估和RT-qPCR,以研究PC潜在的生物学机制。该研究确定ADH1A、ACACB、CD36、CERS4、PDE3B、ALOX5和CRAT为PC的生物标志物。RT-qPCR结果显示,与相邻组织相比,肿瘤样本中ADH1A、ACACB、CD36、CERS4、PDE3B和CRAT的表达降低,而肿瘤样本中ALOX5的表达显著升高。利用这些生物标志物的风险模型将PC患者分为高风险和低风险队列,高风险患者的生存概率较低。随后,风险评分和N分期被确定为独立的预后因素,从而开发出列线图。值得注意的是,两个风险队列在“细胞周期”途径中均显示出显著富集。此外,TP53突变在高风险队列(76%)和低风险队列(50%)中均很普遍。相关性分析表明,PVRL2(一种免疫抑制因子)、CD276(一种免疫激活剂)和CCL20(一种趋化因子)与风险评分的正相关性最高。在本研究中,ADH1A、ACACB、CD36、CERS4、PDE3B、ALOX5和CRAT被确定为PC的生物标志物,并在临床样本中验证了它们的表达水平。这些发现为开发PC的靶向治疗提供了潜在的理论基础。